Blood Coagulation Factors And Fibrin, E.g., Thromboplastin, Etc. Patents (Class 530/381)
  • Patent number: 9938318
    Abstract: The present invention relates to a method or process for the manufacture of a virus and prion save native fibrinogen concentrate of high purity and low amounts of fibrinopeptide A and fibronectin.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: April 10, 2018
    Assignee: OCTAPHARMA AG
    Inventors: Petra Schulz, Rainer Pape, Werner Gehringer
  • Patent number: 9670475
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: June 6, 2017
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Patent number: 9636515
    Abstract: This invention relates to methods for treatment of diseases of ageing including immunosenescence, immune dysfunction, inflammation and impairment of early lymphoid lineage differentiation. The invention more specifically relates to the use of granulocyte colony stimulating factors to assist in stem cell mobilization, optionally in combination with the application of a method of delivering precise magnetic field patterns which agree with the body's own natural magnetic field patterns, and further in combination with re-infusion of previously collected autologous cells and/or plasma, optionally including allogeneic (healthy donor) cells and blood plasma.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: May 2, 2017
    Assignee: ADVANCED NEUROREGENERATIVE THERAPIES, LLC.
    Inventor: Dipnarine Maharaj
  • Patent number: 9410137
    Abstract: Factor Xa variants and methods of use thereof are disclosed.
    Type: Grant
    Filed: December 23, 2012
    Date of Patent: August 9, 2016
    Assignee: The Children's Hospital of Philadelphia
    Inventor: Rodney M. Camire
  • Patent number: 9127089
    Abstract: Highly-purified soluble thrombomodulin which has a content of host cell-originated proteins being in a ratio of less than 10 ng of the proteins per 10,000 U of the soluble thrombomodulin, wherein the soluble thrombomodulin is produced by a transformant cell obtained by transfecting a host cell with a DNA containing a nucleotide sequence encoding the soluble thrombomodulin.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: September 8, 2015
    Assignee: ASAHI KASEI PHARMA CORPORATION
    Inventors: Yuji Ueno, Hiroki Shigematsu
  • Publication number: 20150140021
    Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 21, 2015
    Inventors: Kuo-Jang Kao, Yun-Hsin Wang
  • Patent number: 9023992
    Abstract: The invention described herein provides new methods of preparing purified Factor VII polypeptide drug substances in large quantities (industrial scale levels) that are associated with reduced content of product-related impurities (e.g., late eluting peaks) and/or that exhibit a relatively uniform glycosylation pattern.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Daniel E. Rasmussen, Janus Krarup
  • Patent number: 9012393
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: April 21, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • Patent number: 8981059
    Abstract: A platelet aggregation inducing substance containing as an active ingredient a polypeptide having a peptide fragment represented by formula (1) (component A): -(Pro-X-Gly)n-??(1) wherein X represents Pro or Hyp; and n represents an integer of from 20 to 5,000.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: March 17, 2015
    Assignee: JNC Corporation
    Inventors: Yasuto Umeda, Shinichi Takasaki, Takafumi Takebayashi, Takahiro Kawai
  • Patent number: 8945897
    Abstract: The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: February 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Richard Sheinecker, Hanspeter Rottensteiner, Peter Turecek
  • Publication number: 20150018525
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Application
    Filed: July 23, 2014
    Publication date: January 15, 2015
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt
  • Patent number: 8932820
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 13, 2015
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • Publication number: 20150010494
    Abstract: A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Gord Adamson, David Bell, Steven Brookes
  • Patent number: 8921317
    Abstract: A fibrin-based hemostatic agent suitable for both civilian and military use is disclosed. The hemostatic agent comprises (i) nanoparticles to which a plurality of Knob-A recognition sequences are attached, and (ii) coiled-coils of recombinantly-produced human fibrinogen ? and chains and the ? chain globular domain. A delivery system for the hemostatic agent also is disclosed, which additionally comprises means for delivering (i) and (ii) to a wound site. The delivery means may be a CO2 canister or a shaker jet.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: December 30, 2014
    Assignee: BAE Systems Information and Electronic Systems Integration Inc.
    Inventor: Robert A. Burton
  • Publication number: 20140369994
    Abstract: Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 18, 2014
    Inventors: William N. Drohan, Michael J. Griffith
  • Patent number: 8865868
    Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: October 21, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Carsten Behrens, Patrick William Garibay, Søren Østergaard, Henrik Sune Andersen, Nils Langeland Johansen, Bernd Peschke, Sonja Bak
  • Patent number: 8859731
    Abstract: A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: October 14, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Mikael Kofod-Hansen, Henning Ralf Stennicke, Soeren Oestergaard, Henrik Oestergaard
  • Publication number: 20140303353
    Abstract: The present application relates to methods for purifying recombinant coagulation factor proteins, including for example, prothrombin (Factor II). In embodiments, the methods provide purified prothrombin that exhibit increased bioactivity and reduced levels of thrombin, thereby increasing the safety of the prothrombin. Also provided are purified recombinant coagulation factor proteins.
    Type: Application
    Filed: August 31, 2012
    Publication date: October 9, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Alan Hunter, Xiangyang Wang, Timothy Pabst, Michaela Wendeler, Jihong Wang, Kendall Carey, Robert Strouse, Johnson Varghese
  • Publication number: 20140303084
    Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.
    Type: Application
    Filed: June 9, 2012
    Publication date: October 9, 2014
    Applicant: Biogen IDEC MA Inc.
    Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
  • Publication number: 20140295496
    Abstract: The present invention provides a recombinant baculovirus. The baculovirus has a genome into which a gene encoding ?-glutamyl carboxylase (GGCX) and a gene encoding DT-diaphorase (NQO1) are incorporated. The present invention further provides a method for producing a recombinant vitamin K-dependent protein by using the recombinant baculovirus.
    Type: Application
    Filed: March 27, 2014
    Publication date: October 2, 2014
    Applicant: SYSMEX CORPORATION
    Inventors: Takahiko BANDO, Mutsumi SUGAI
  • Patent number: 8822643
    Abstract: The present invention provides a process for purifying FV starting from human plasma or a fractionation intermediate thereof, that is simple, scalable to the industrial level and relatively inexpensive compared to the methods described in the literature to date. The invention consists of the use of two anion exchange chromatography steps, the first of which has the purpose of separating the FV from the PTC component factors, while the second has the purpose of isolating the protein of interest from the majority of plasma proteins by means of selective interaction with the weak anion exchange support used. The process developed has also had a viral inactivation step and a viral removal step included, contributing to the safety of the final product obtained, without however significantly altering the process total recovery of FV, and without necessitating the introduction of additional steps for eliminating the inactivating agents used, thanks to the order in which the various steps are conducted.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: September 2, 2014
    Assignee: Kedrion S.p.A.
    Inventors: Paola Rossi, Ilaria Nardini, Pierangelo Giovacchini, Filippo Mori, Claudio Farina
  • Patent number: 8816054
    Abstract: Factor VIII variants and methods of use thereof are disclosed.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: August 26, 2014
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Valder Arruda, Rodney M. Camire, Nicholas Iacobelli
  • Patent number: 8809501
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: August 19, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 8754194
    Abstract: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: June 17, 2014
    Assignee: CSL Behring GmbH
    Inventors: Stefan Schulte, Thomas Weimer, Hubert Metzner
  • Patent number: 8741845
    Abstract: ClotBlock is a lyophilized fibrin hemostatic designed for use an adjunct or primary treatment in moderate to severe hemorrhage. It can be applied directly to the wound in a laparotomy procedure or as non-invasive sealant. Its crosslinking technology generates a strong and safe adhesive fibrin sealant required for high volume hemostasis. The attachment properties of the cake as well as the rapid formation of and stability of the fibrin clot ensures that a strong stable fibrin clot is formed within 1 to 5 minutes depending on the grade of the wound. The agent is safe, biocompatible, biodegradable and can be stored at room temperature for one year.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: June 3, 2014
    Assignee: Biomedica Mangement Corporation
    Inventors: George David Falus, Leonid Medved
  • Patent number: 8741844
    Abstract: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: June 3, 2014
    Assignee: Universite Paris-Sud XI
    Inventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini
  • Patent number: 8741286
    Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: June 3, 2014
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
  • Publication number: 20140141488
    Abstract: Sequence of 55 New Found Proteins—2 new proteins in Cryoprecipitate—8 new proteins in Fraction III—8 new proteins in Prothrombin Complex Concentrate—2 new found proteins in AFCC (Fraction 33)—3 new proteins in Fraction IV and 4 new found proteins in AFOD (Fraction 42)—2 in HemoRAAS®, 3 in FibroRAAS®, 5 in GammaRAAS®, 3 in AFCC®, 1 in Fraction 3-2, 2 in Fraction 3, 4 in FibingluRAAS® (Thrombin), 3 in AFOD®, 1 in AlbuRAAS®, 1 in FibingluRAAS® (High concentrate Fibrinogen), 1 in AFCC® (From fraction IV), 2 in Transferrin from Human Plasma and their name KH1 through KH55, and 16 existing proteins in which good KH healthy cells exists and their application.
    Type: Application
    Filed: January 31, 2013
    Publication date: May 22, 2014
    Inventor: Kieu Hoang
  • Publication number: 20140121351
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Application
    Filed: December 20, 2013
    Publication date: May 1, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Stefan Haider, Andreas Ivens, Hanspeter Rottensteiner, Juregen Siekmann, Peter Turecek
  • Publication number: 20140107320
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 17, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Stefan Haider, Hanspeter Rottensteiner, Juergen Siekmann, Peter Turecek
  • Patent number: 8697844
    Abstract: The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood coagulation factors such as Factor IX (FIX), to proteins purified by said method and to the use of said purified proteins in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: April 15, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Matthias Karl Dietrich Wiendahl, Lars Sejersgaard, Are Bogsnes
  • Patent number: 8686117
    Abstract: A platelet aggregation inducing substance containing as an active ingredient a polypeptide having a peptide fragment represented by formula (1) (component A): -(Pro-X-Gly)n-??(1) wherein X represents Pro or Hyp; and n represents an integer of from 20 to 5,000.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: April 1, 2014
    Assignee: JNC Corporation
    Inventors: Yasuto Umeda, Shinichi Takasaki, Takafumi Takebayashi, Takahiro Kawai
  • Patent number: 8686225
    Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: April 1, 2014
    Assignee: Ventria Bioscience Inc.
    Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
  • Patent number: 8680240
    Abstract: ClotFoam is a sealant and hemostatic agent for use in cases of non-compressible hemorrhage for moderate to severe bleeding. It can be applied in the operating room through laparoscopic ports, or directly over lacerated tissue in laparotomy procedures or outside the operating room through a mixing needle and/or a spray injection method following intracavitary severe trauma or surgery. Its crosslinking technology generates an adhesive scaffold that carries a fibrin sealant required for hemostasis. Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The composition is biocompatible and non-inflammatory. The invention uses fibrin monomer polymerized by a change of pH as active sealing component. The viscoelastic properties of the foam as well as the rapid formation of a fibrin clot ensure that the sealant remains at the site of application without being washed away by blood.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: March 25, 2014
    Inventor: George David Falus
  • Publication number: 20140058790
    Abstract: Methods and compositions described herein relate to processes for the production of deuterated peptides, and the deuterated peptides produced accordingly. Deuterated peptides produced according to methods and compositions described herein may be produced more efficiently than such peptides produced according to prior art processes. The production process of according to methods and compositions described herein may lead to advantages in yield, purity, and/or price for deuterated peptides. Methods of marketing deuterated peptides are also disclosed.
    Type: Application
    Filed: November 30, 2011
    Publication date: February 27, 2014
    Applicant: AmideBio LLC
    Inventors: Michael H.B. Stowell, Mikhail Plam
  • Patent number: 8658597
    Abstract: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: February 25, 2014
    Assignee: Novo Nordisk HealthCare AG
    Inventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
  • Publication number: 20140046028
    Abstract: The invention concerns a concentrate of human Factor XI having high specific activity prepared using a method comprising a filtration-adsorption step and a chromatography step on cation exchange resin. The concentrate obtained is fully adapted for therapeutic use as substitution therapy in cases of Factor XI deficiency.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 13, 2014
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventor: Jean-François Martin
  • Publication number: 20140044796
    Abstract: The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives.
    Type: Application
    Filed: February 10, 2012
    Publication date: February 13, 2014
    Applicant: OXPROTECT GMBH
    Inventors: Beate Kehrel, Martin Brodde
  • Publication number: 20140039160
    Abstract: The present invention provides a process for purifying FV starting from human plasma or a fractionation intermediate thereof, that is simple, scalable to the industrial level and relatively inexpensive compared to the methods described in the literature to date. The invention consists of the use of two anion exchange chromatography steps, the first of which has the purpose of separating the FV from the PTC component factors, while the second has the purpose of isolating the protein of interest from the majority of plasma proteins by means of selective interaction with the weak anion exchange support used. The process developed has also had a viral inactivation step and a viral removal step included, contributing to the safety of the final product obtained, without however significantly altering the process total recovery of FV, and without necessitating the introduction of additional steps for eliminating the inactivating agents used, thanks to the order in which the various steps are conducted.
    Type: Application
    Filed: April 20, 2012
    Publication date: February 6, 2014
    Applicant: KEDRION S.P.A.
    Inventors: Paola Rossi, Ilaria Nardini, Pierangelo Giovacchini, Filippo Mori, Claudio Farina
  • Patent number: 8642738
    Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 4, 2014
    Assignee: Regents of the University of Minnesota
    Inventor: Gary L. Nelsestuen
  • Patent number: 8642737
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: February 4, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Andreas Ivens, Peter Turecek, Oliver Zoechling
  • Patent number: 8637640
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: January 28, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 8618258
    Abstract: Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: December 31, 2013
    Assignee: Prochon Biotech Ltd.
    Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
  • Publication number: 20130347134
    Abstract: The present invention provides, inter alia, transgenic non-human animals, such as transgenic mice. The animals contain in their genome a polynucleotide encoding a von Willebrand factor (VWF) polypeptide, which polypeptide forms a thrombus when in the presence of human platelets. Nucleic acid sequences and vectors for generating the transgenic non-human animals, and methods for using the transgenic non-human animals are provided as well. Chimeric VWF proteins are also provided.
    Type: Application
    Filed: June 20, 2013
    Publication date: December 26, 2013
    Inventors: Thomas Diacovo, Jianchun Chen
  • Publication number: 20130337479
    Abstract: The present invention aims to provide methods to detect cognitive impairment including mild cognitive impairment and Alzheimer disease by using a protein or its partial peptide that differs in presence or absence, or in quantity between non-cognitive impairment and patients with cognitive impairment and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect cognitive impairment including Alzheimer disease or mild cognitive impairment. Specifically, a biomarker for diagnosis of psychiatry disease or cognitive impairment comprising protein fragment or peptide of not less than 5 amino acid residues arising from at least one protein or peptide selected from the group of proteins consisting of amino acid sequence expressed by SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25 and selected from the group of partial peptide in these proteins consisting of amino acid sequence expressed by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 27.
    Type: Application
    Filed: December 21, 2011
    Publication date: December 19, 2013
    Applicant: MCBI INC.
    Inventors: Kazuhiko Uchida, Kohji Meno, Hideaki Suzuki
  • Patent number: 8598319
    Abstract: The invention is related to a process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing freeze-dried concentrates of said proteins comprising the steps of: chromatographic purification comprising the steps of loading an anion exchanger of weak base type with the said solubilized fraction, previously equilibrated with a buffer of a predetermined ionic strength of an alkaline pH, which allows to retain the biological glue, elution of the biological glue by increasing the ionic strength of the said buffer, and separation of FXIII from fibrinogen by addition to at least one part of the biological glue eluate of at least one chemical agent precipitating the FXIII, and recovery of the resulting purified fibrinogen containing supernatant solution, and diafiltration of the fibrinogen, biological glue and resolubilized FXIII solutions, followed by a freeze-drying of said solutions.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: December 3, 2013
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Nogré Michel, Porte Pierre, Tellier Michel
  • Publication number: 20130317197
    Abstract: The present invention relates to a method for capturing virus-like particles of interest from a mixture comprising the use of an expanded bed of adsorbent; suitably wherein said method comprises the steps of: (a) providing an expanded bed of adsorbent; (b) contacting the mixture with the adsorbent such that the constituents of the mixture contact the expanded bed of adsorbent; (c) optionally washing the adsorbent; and (d) optionally eluting the particle of interest from the adsorbent.
    Type: Application
    Filed: October 27, 2011
    Publication date: November 28, 2013
    Applicant: PHILIP MORRIS PRODUCTS S.A.
    Inventors: Allan Lihme, Karen Oishi, Inga Vaarst, Rosa Cabrera
  • Publication number: 20130295646
    Abstract: The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing the protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and an ionic characteristic in pH conditions enabling the protein to be retained on the substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluted fraction by removing the milk proteins from the eluted fraction; and e) recovering the protein.
    Type: Application
    Filed: June 5, 2013
    Publication date: November 7, 2013
    Applicant: LFB BIOTECHNOLOGIES
    Inventors: Alain LEJARS, Michel Nogre, Monique Ollivier
  • Patent number: 8575102
    Abstract: The present invention provides conjugates encompassed by the following structure, wherein: D is a residue of an active agent bearing at least one amino group; and PEG-m is a methoxy end-capped poly(ethylene glycol), and further wherein the active agent is a coagulation factor having a molecular weight of greater than 100 kDa. Methods of making conjugates, and methods for administering conjugates, are also provided.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: November 5, 2013
    Assignee: Nektar Therapeutics
    Inventors: Sean M. Culbertson, Samuel P. McManus, Mary J. Bossard
  • Publication number: 20130289246
    Abstract: The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of influenza virus infections. In particular, these antibodies may neutralize or limit the replication of influenza virus. Also disclosed are improved methods for producing such monoclonal antibodies, including novel immunogens for use in vaccination and production of protective immune responses.
    Type: Application
    Filed: September 30, 2011
    Publication date: October 31, 2013
    Applicant: VANDERBILT UNIVERSITY
    Inventors: James E. Crowe, Jens C. Krause, David L. Blum